All News

USA,States,map

Rheumatology Supply and Demand (2009 - 2024)

Jack Cush, MD

A retrospective review of US rheumatology manpower and training between 2009 and 2024 shows that US rheumatology training has become competitive with an increasing surplus of applicants compared to available training positions, which have also increased over time.

Read Article
WashDC4.jpg

ACR Applauds Bipartisan Support for Prior Authorization Reform Bill

ACR

The American College of Rheumatology (ACR) today commended the more than 295 bipartisan, bicameral cosponsors of The Improving Seniors’ Timely Access to Care Act, which, if enacted, would reform the prior authorization process for Medicare Advantage plans.

Read Article
interview,magnify,woman

The Interview (11.7.2025)

Jack Cush, MD

I've done thousands of interviews; mostly for medical school admissions or medical and research employment.  They’re all the same. I'm looking for the “right one” and the interviewee is somewhere between apprehension, uncertainty and hope.  From all this experience I’ve developed my own perspective on interviews and interviewing that has been amended in the digital/virtual era.

Read Article
cost.healthcare.jpg

Beyond the Breakthrough: Equity and Access in CAR-T Cell Therapy for RA

Bella Mehta, MBBS, MS

At ACR Convergence 2025, abstract 1039 entitled, “Global Cost-Effectiveness and Equity in CAR-T Cell Therapy for Rheumatoid Arthritis” adds a critical dimension to the growing enthusiasm around cellular therapies in autoimmune disease.

Read Article
kneepain3.jpg (keep)

Arthritis Pain and Education Gaps Linked

EurekAlert!

New research from The University of Texas at Arlington shows that differences in state welfare policies are linked to rising arthritis-related joint pain across much of the U.S.

Read Article
RheumNow Podcast square

Eating Crow (10.10.2025)

Jack Cush, MD

Dr. Jack Cush reviews the news, FDA approvals, and journal articles. In this episode: HMGCR Abs, FDA approvals and Cush eats crow.

Read Article
Fracture%20bone.png (keep)

NY Times on Osteoporosis in Men

Jack Cush, MD

The NY Times has addressed the problem of osteoporosis in men noting a need for increased awareness and screening. Takeaways:

Read Article
PSA2L.jpg

Gender Complexities in Psoriatic Arthritis Treatment Outcomes

Jack Cush, MD

Analysis of a German psoriatic arthritis (PsA) patients registry demonstrates sex-specific differences regarding clinical manifestation and treatment outcomes, especially with regard to drug discontinuations.

Read Article
op.compare.jpg

Osteoporosis Screening in High-Risk Men

Jack Cush, MD

A Veterans Affairs (VA) Health Systems study of older male veterans found benefits of a remote model of screening that significantly improved osteoporosis screening, treatment, and adherence compared with usual care, with high patient and clinician acceptance.

Read Article
There is a growing burden of #OA among middle-aged adults, rising by 123.7%, from 11.8 million in 1990 to 26.4 million in 2021. 56.5% of incident cases & 38% of prevalent cases occur in middle-aged group (70% higher than the elderly (>60 years) population). Highest in hi-income. https://t.co/JVpZ96qe0E
Dr. John Cush RheumNow ( View Tweet)
Beyond the Breakthrough: Equity and Access in CAR-T Cell Therapy for RA At #ACR25, abstract 1039, "Global Cost-Effectiveness and Equity in CAR-T Cell Therapy for Rheumatoid Arthritis," highlights the critical economic and ethical dimensions of CAR-T cell therapy in autoimmune https://t.co/Rci0dL7THj
Dr. John Cush RheumNow ( View Tweet)
FDA is going to "fast-track" biosimilars to curtail the costs of expensive biologics https://t.co/h5NBsUaM97

Links:

Dr. John Cush RheumNow ( View Tweet)

@Janetbirdope’s #ACR25 pearls remind us: Order ANA only when clinical suspicion exists Never repeat a positive ANA ENA only if ANA+ ❌ Ignore dsDNA if ANA– (except anti-Ro52) Stop serial dsDNA/C3/C4 if stable Smart lab use saves patients anxiety and systems money. #SLE https://t.co/Mu3EefcIx0

Links:

Romatolog Nurullah_Akkoc ( View Tweet)
CDAI appropriately guided therapy escalation in RA, but not for everyone. Treatment adjustments were less likely in pts with public or no insurance. Even data-driven care can fall short when access barriers persist. @RheumNow #ACR25 Abstract#2616

Jiha Lee JihaRheum ( View Tweet)

Reaadmissions in sle pregnancies from 66k patients Insurance and economics seem to be very important in predictions using machine learning. Abst#2629 #ACR25 @RheumNow https://t.co/x2oo9TOxoh

Links:

Bella Mehta bella_mehta ( View Tweet)
Starting biologic early could save more than joints. In 329 RA pts, first-line anti-TNF reduced testing and hospitalization costs vs csDMARDs across Europe. Earlier targeted therapy pay off in outcomes and economics. @RheumNow #ACR25 Abstract#2271 https://t.co/zZ32CpT36d

Links:

Jiha Lee JihaRheum ( View Tweet)
Bremer et al. Earlier initiation of biosimilar adalimumab (vs csDMARDs) may result in cost-savings. Reduced cost of tests, consultations, and hospitalisations. @RheumNow #ACR25 Abstr#2271 https://t.co/lHaSiX3WLd

Links:

Richard Conway RichardPAConway ( View Tweet)
Simko et al. 6-monthly vs 3-monthly MTX lab monitoring. 3821 patients. Appears to be no difference. Potential for significant cost-savings and reduced burden to patients. @RheumNow #ACR25 Abstr#1370 #ACRbest https://t.co/G3tNQq8qXT

Links:

Richard Conway RichardPAConway ( View Tweet)
Rheum guidelines balance data & context. Beyond evidence, factors like cost, equity & feasibility shape recs. GRADE-ADOLOPMENT = global tool to adopt, adapt, or design local guidance for more rapid integration and with less $$$ @RheumNow #ACR25 #GlobalRheumSummitt https://t.co/Sfsqxsqpt4

Links:

Jiha Lee JihaRheum ( View Tweet)
Meniscal tears - Systematic review of 46 studies - Incidence of 66 per 100,000 - Annual cost of 5 billion to US healthcare - Trend to preserve the meniscus, do less removal, more preservation - Biologic Rx (platelet-rich plasma & stem cell Rx) inconclusive results https://t.co/IPyRFad9GX
Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×